A detailed history of Advisor Group Holdings, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 281,467 shares of RXRX stock, worth $1.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
281,467
Previous 219,948 27.97%
Holding current value
$1.84 Million
Previous $1.65 Million 12.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.92 - $8.6 $364,192 - $529,063
61,519 Added 27.97%
281,467 $1.85 Million
Q2 2024

Aug 13, 2024

BUY
$7.35 - $10.05 $899,757 - $1.23 Million
122,416 Added 125.51%
219,948 $1.65 Million
Q1 2024

May 10, 2024

BUY
$9.13 - $15.52 $341,699 - $580,851
37,426 Added 62.27%
97,532 $972,000
Q4 2023

Feb 12, 2024

BUY
$5.09 - $10.79 $269,841 - $572,021
53,014 Added 747.52%
60,106 $592,000
Q3 2023

Nov 13, 2023

BUY
$6.59 - $15.86 $25,628 - $61,679
3,889 Added 121.42%
7,092 $54,000
Q2 2023

Aug 10, 2023

BUY
$4.56 - $9.94 $588 - $1,282
129 Added 4.2%
3,203 $23,000
Q1 2023

May 12, 2023

SELL
$6.42 - $9.64 $5,842 - $8,772
-910 Reduced 22.84%
3,074 $20,000
Q4 2022

Feb 10, 2023

BUY
$7.16 - $12.7 $4,288 - $7,607
599 Added 17.7%
3,984 $30,000
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $5,050 - $8,772
645 Added 23.54%
3,385 $36,000
Q2 2022

Aug 10, 2022

SELL
$5.04 - $9.26 $5,382 - $9,889
-1,068 Reduced 28.05%
2,740 $22,000
Q1 2022

May 04, 2022

BUY
$6.16 - $18.03 $8,704 - $25,476
1,413 Added 59.0%
3,808 $27,000
Q3 2021

Nov 05, 2021

BUY
$19.03 - $41.33 $9,610 - $20,871
505 Added 26.72%
2,395 $54,000
Q2 2021

Aug 02, 2021

BUY
$18.0 - $37.42 $34,020 - $70,723
1,890 New
1,890 $69,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.18B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.